Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects

Diabetes Obes Metab. 2022 Apr;24(4):757-762. doi: 10.1111/dom.14627. Epub 2022 Jan 2.

Authors

Soo Lim¹, Minji Sohn¹, Yujin Shin¹, Ele Ferrannini²

Affiliations

¹ Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
² CNR Institute of Clinical Physiology, Pisa, Italy.

PMID: 34908220
DOI: 10.1111/dom.14627

No abstract available

Keywords: SGLT2 inhibitor; drug mechanism; type 2 diabetes.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Benzhydryl Compounds / adverse effects
Diabetes Mellitus, Type 2* / metabolism
Drug Therapy, Combination
Glucosides / adverse effects
Glycated Hemoglobin / metabolism
Humans
Hypoglycemic Agents / adverse effects
Metformin* / adverse effects
Sitagliptin Phosphate / adverse effects
Treatment Outcome

Substances

Benzhydryl Compounds
Glucosides
Glycated Hemoglobin A
Hypoglycemic Agents
Metformin
empagliflozin
Sitagliptin Phosphate